January 2009

► NEW DRUGS	Standard Plan	Select Plan	Closed Plan
No new drugs reviewed at December meeting

► LINE EXTENSIONS	Standard Plan	Select Plan	Closed Plan
Stavzor (valproic acid, delayed release capsules)
indicated for the treatment of manic episodes associated with bipolar disorder, and as monotherapy and adjunctive therapy in the treatment of adult and pediatric patients age 10 and above with complex partial seizures, simple and complex absence seizures, or multiple seizure types. Also indicated for prophylaxis of migraine headaches. In a limited category (Anti-convulsants)	Brand copay.	Third tier, non-preferred brand copay.	Not covered.

► DRUG CLASS REVIEW Oral Bisphosphonates	Standard Plan	Select Plan	Closed Plan
alendronate
Full Class Review of oral bisphosphonates used in the prevention and treatment of osteoporosis. Generic agents listed. Quantity limits apply DACON edits apply	First tier, generic copay. Coverage determined by the benefit design chosen by the plan sponsor.	First tier, generic copay. Coverage determined by the benefit design chosen by the plan sponsor.	First tier, generic copay. Coverage determined by the benefit design chosen by the plan sponsor.
Actonel, Actonel with Calcium, Boniva, Fosamax Oral Solution
Full Class Review of oral bisphosphonates used in the prevention and treatment of osteoporosis. Preferred agents listed. Quantity limits apply DACON edits apply	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.
Fosamax, Fosamax Plus D
Full Class Review of oral bisphosphonates used in the prevention and treatment of osteoporosis. Non-preferred agents listed. Quantity limits apply DACON edits apply	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Third tier, non-preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Not covered.

► PPL UPDATES	Standard Plan	Select Plan	Closed Plan
Relistor (methylnaltrexone bromide, for subcutaneous injection)
Indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Relistor is added to Tier 2, effective February 1, 2009. Prior Authorization applies	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.

► BRANDS WITH GENERICS AVAILABLE	Standard Plan	Select Plan	Closed Plan
Imitrex (sumatriptan succinate) tablets and injection
Indicated for the acute treatment of migraine attacks with or without aura. Imitrex injection is also indicated for the acute treatment of cluster headache episodes. Imitrex Tablets and Imitrex Injection are being removed from preferred status because generic equivalents, sumatriptan succinate tablet and sumatriptan succinate injection, are available at the generic copay. Quantity limits apply. In a limited category (Migraine)	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Third tier, non-preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Not covered.
Keppra (levetiracetam)
Indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy, and as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy, and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. Keppra is being removed from preferred status because the generic equivalent, levetiracetam is available at the generic copay. In a limited category (Anticonvulsants)	Brand copay.	Third tier, non-preferred brand copay.	Not covered.

► Clinical Programs: DACON	Standard Plan	Select Plan	Closed Plan
Accolate, Adderall/XR, Avodart, Celebrex, Effexor XR, Evista, Flomax, Lexapro, Plavix, Prandin, Strattera
Listed items will be added to the DACON program, effective March 1, 2009.	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.
Emsam, Proscar, Sarafem, Starlix
Listed items will be added to the DACON program, effective March 1, 2009.	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Third tier, non-preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Not covered.

► Clinical Programs: Quantity Limits	Standard Plan	Select Plan	Closed Plan
Fortical
Listed items will be added to the Quantity Limits program, effective March 1, 2009.	First tier, generic copay. Coverage determined by the benefit design chosen by the plan sponsor.	First tier, generic copay. Coverage determined by the benefit design chosen by the plan sponsor.	First tier, generic copay. Coverage determined by the benefit design chosen by the plan sponsor.
Fosamax Oral Solution, Miacalcin
Listed items will be added to the Quantity Limits program, effective March 1, 2009.	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.
Prozac Weekly
Listed items will be added to the Quantity Limits program, effective March 1, 2009.	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Third tier, non-preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Not covered.

	January 2009



Innoviant's Business Committee meets monthly to evaluate product status (tier placements) and new prescription products approved by the Food and Drug Administration (FDA). Decisions made by the Innoviant Business Committee are based on information and recommendations provided by Prescription Solutions' National Pharmacy & Therapeutics Committee (NPTC). The P&T is comprised of independent physician providers, affiliated plan physicians and pharmacists. The following table summarizes the decisions made at the December committee meetings. All changes are effective March 1, 2009 unless otherwise noted. Current information related to Innoviant and its offerings is available at www.innoviant.com. A copy of this newsletter can also be found on the website (http://www.innoviant.com/customers/publications/default.asp).